Atlas Trials

Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV

Clinical trial NCT01166126 · TERMINATED

Trial details

NCT number
NCT01166126
Sponsor
National Cancer Institute (NCI)
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Mucosal MelanomaRecurrent MelanomaStage IV Melanoma
Start date
2010-10-01
Primary completion
2012-06-01
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.